Immunovant, Inc. financial statements
Immunovant, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
FY2026
| Revenue | USD 0 | EODHD |
| Net income | −USD 505.61M | 10-K |
| Cash and equivalents | USD 902.11M | 10-Q |
| Total debt | USD 72K | EODHD |
Immunovant, Inc. financials on 6ix · Immunovant, Inc. on 6ix